Lexeo Therapeutics selloff looks ‘highly unwarranted,’ says H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $13 price target on Lexeo Therapeutics (LXEO), saying Monday’s selloff looks “highly unwarranted” given the company’s data integrity and forward-aligned FDA dialogue. Lexeo’s concurrent-control design is exactly what the modern FDA wants to see, not what it is pushing back on, the analyst says, adding that Lexeo’s alignment was reached under a new guard, positioning it firmly within today’s regulatory expectations. The firm also noted that it views Lexeo as one of the few gene-therapy developers that pre-emptively designed to the FDA’s post-reorganization, post-Marks standard for evidence generation, and that the roughly 10% selloff reflects confusion between the regulatory tightening and regulatory alignment and creates a clear buying opportunity.